New pill could ease severe psoriasis in just 12 weeks

NCT ID NCT07251998

Recruiting now Disease control Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests an experimental oral drug called ICP-332 against a placebo in 172 adults with moderate-to-severe plaque psoriasis. Participants take the drug or placebo daily for 12 weeks. The main goal is to see if at least 75% of skin symptoms improve. If it works, ICP-332 could become a new treatment option for people with this chronic skin condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ICP-332 (an experimental oral drug)
What this could lead to: If successful, this could lead to a new oral treatment option for people with moderate-to-severe plaque psoriasis.
What could go wrong: This is a mid-stage trial with only 172 participants, so results may not apply to everyone. The drug may not prove more effective than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

Shanghai Dermatology Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200443, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.